Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Raytheon Technologies Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Raytheon Technologies Corp trades at $196.2 (market cap $263.86B). The key difference: Raytheon Technologies Corp is far larger — about 6.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Raytheon Technologies Corp pays a 1.49% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RTX | |
|---|---|---|
Market Cap | $39.89B | $263.86B |
Sector | Health | Industrials |
52-Week High | $491.22 | $212.16 |
52-Week Low | $278.09 | $146.87 |
Enterprise Value | $38.15B | $295.97B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RTX trades at $195.93, up 0.37% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026 EPS of $1.78 versus $1.51 expected, highlight robust operational performance. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.03%. The company secured a $515 million U.S. Navy contract for SPY-6 radars (PRNewsWire, 2026-06-03), reinforcing its defense segment strength.
The outlook is positive, driven by defense contract wins and commercial aerospace recovery, but risks include debt levels and geopolitical uncertainties. With a consensus price target of $213.00 (18 buy, 8 hold, 0 sell), the stock offers potential upside, though valuation multiples like a P/E of 36.76 warrant monitoring amid interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
